title: Interferon system in women with genital papillomavirus infection receiving immunomodulatory therapy.
abstract: The interferon system was studied in women with genital papillomavirus infection. In most patients the interferon system was activated, while the ability of lymphocytes to respond to inductors decreased. Laserotherapy and immunomodulatory therapy with larifan, ridostin, and viferon for 1 month normalized blood interferon concentration (39.4% patients) and interferon-gamma production by lymphocytes in response to inductors (87.9% patients). After laser monotherapy these parameters returned to normal only in 13.2 and 7.6% patients, respectively. Correlation and regression analyses showed that changes in the interferon system were synchronized after immunomodulatory therapy. These data indicate that immunomodulatory therapy produces a complex effect on the interferon system. Measurements of blood interferon level can be used to predict the effect of further treatment with interferon-gamma inductors.
authors.affiliation: Research Center for Obstetrics, Gynecology, and Perinatology, Russian Academy of Medical Sciences, Moscow.
authors.forename: S I
authors.initials: SI
authors.lastname: Rogovskaya
authors.forename: A V
authors.initials: AV
authors.lastname: Zhdanov
authors.forename: N S
authors.initials: NS
authors.lastname: Loginova
authors.forename: L Z
authors.initials: LZ
authors.lastname: Faizullin
authors.forename: V N
authors.initials: VN
authors.lastname: Prilepskaya
authors.forename: L V
authors.initials: LV
authors.lastname: Van'ko
authors.forename: G T
authors.initials: GT
authors.lastname: Sukhikh
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use; D007370:Interferon Type I / Q000627:therapeutic use; D007372:Interferons / Q000097:blood*; D009930:Organic Chemicals; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000276:immunology*; D012330:RNA, Double-Stranded / Q000627:therapeutic use; D012331:RNA, Fungal / Q000627:therapeutic use; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000975:Antioxidants; D007369:Interferon Inducers; D007370:Interferon Type I; D009930:Organic Chemicals; D012330:RNA, Double-Stranded; D012331:RNA, Fungal; D011994:Recombinant Proteins; C076741:ridostin; C066530:larifan; D007372:Interferons